Legacy Capital Wealth Partners LLC Purchases New Holdings in Exact Sciences Corporation $EXAS

Legacy Capital Wealth Partners LLC acquired a new position in Exact Sciences Corporation (NASDAQ:EXAS) during the 4th quarter, according to the company in its most recent Form 13F filing with the Securities & Exchange Commission. The fund acquired 41,837 shares of the medical research company’s stock, valued at approximately $42,000.

A number of other institutional investors have also recently bought and sold shares of EXAS. Integrated Wealth Concepts LLC purchased a new stake in shares of Exact Sciences during the 1st quarter valued at $604,000. MIRAE ASSET GLOBAL ETFS HOLDINGS Ltd. boosted its holdings in shares of Exact Sciences by 11.8% in the 1st quarter. MIRAE ASSET GLOBAL ETFS HOLDINGS Ltd. now owns 21,186 shares of the medical research company’s stock worth $921,000 after buying an additional 2,231 shares during the last quarter. Great Lakes Advisors LLC boosted its holdings in shares of Exact Sciences by 3.7% in the 1st quarter. Great Lakes Advisors LLC now owns 4,971 shares of the medical research company’s stock worth $215,000 after buying an additional 178 shares during the last quarter. Focus Partners Wealth grew its position in Exact Sciences by 12.6% during the first quarter. Focus Partners Wealth now owns 21,548 shares of the medical research company’s stock valued at $933,000 after buying an additional 2,413 shares during the period. Finally, Prudential Financial Inc. increased its holdings in Exact Sciences by 255.4% during the second quarter. Prudential Financial Inc. now owns 34,720 shares of the medical research company’s stock worth $1,845,000 after buying an additional 24,951 shares during the last quarter. Institutional investors own 88.82% of the company’s stock.

Analyst Ratings Changes

Several brokerages have commented on EXAS. Evercore set a $105.00 price objective on shares of Exact Sciences and gave the stock an “in-line” rating in a research report on Monday, January 5th. Mizuho restated a “neutral” rating and set a $105.00 price target (up from $85.00) on shares of Exact Sciences in a research note on Tuesday, January 20th. BTIG Research reaffirmed a “neutral” rating on shares of Exact Sciences in a report on Tuesday, March 24th. Weiss Ratings reissued a “sell (d-)” rating on shares of Exact Sciences in a report on Thursday, January 22nd. Finally, Zacks Research downgraded Exact Sciences from a “strong-buy” rating to a “hold” rating in a research report on Friday, January 30th. Twenty-one analysts have rated the stock with a Hold rating and one has given a Sell rating to the stock. According to MarketBeat.com, Exact Sciences currently has a consensus rating of “Reduce” and an average target price of $92.13.

Exact Sciences Price Performance

NASDAQ EXAS opened at $104.91 on Friday. The company has a quick ratio of 2.17, a current ratio of 2.43 and a debt-to-equity ratio of 0.97. The company has a market cap of $20.03 billion, a PE ratio of -95.37, a price-to-earnings-growth ratio of 2.02 and a beta of 1.41. Exact Sciences Corporation has a 52 week low of $38.81 and a 52 week high of $104.98. The firm’s 50-day simple moving average is $103.57 and its two-hundred day simple moving average is $89.19.

Exact Sciences (NASDAQ:EXAS) last posted its earnings results on Friday, February 13th. The medical research company reported ($0.21) earnings per share for the quarter, missing the consensus estimate of $0.08 by ($0.29). Exact Sciences had a positive return on equity of 0.53% and a negative net margin of 6.40%.The business had revenue of $878.38 million during the quarter, compared to analysts’ expectations of $860.59 million. During the same quarter in the previous year, the business earned ($0.06) EPS. Exact Sciences’s revenue for the quarter was up 23.1% on a year-over-year basis. Research analysts predict that Exact Sciences Corporation will post -0.58 earnings per share for the current year.

Exact Sciences Company Profile

Exact Sciences Corporation is a molecular diagnostics company headquartered in Madison, Wisconsin, dedicated to the early detection and prevention of cancer. The company’s flagship product, Cologuard®, is a noninvasive, stool-based DNA screening test for colorectal cancer that was developed in collaboration with the Mayo Clinic. By combining DNA mutation analysis with hemoglobin detection, Cologuard aims to improve screening adherence and identify cancers and precancerous lesions in average-risk adults.

Since its founding in 1995, Exact Sciences has expanded its portfolio through strategic acquisitions and internal research and development.